Antibody data
- Antibody Data
- Antigen structure
- References [8]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 9292 - Provider product page
- Provider
- Cell Signaling Technology, Inc
- Proper citation
- Cell Signaling Technology Cat#9292, RRID:AB_331419
- Product name
- Bad Antibody
- Antibody type
- Polyclonal
- Reactivity
- Human, Mouse, Rat, Simian
- Host
- Rabbit
- Storage
- -20°C
Submitted references ROS-dependent phosphorylation of Bax by wortmannin sensitizes melanoma cells for TRAIL-induced apoptosis.
PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma.
Novel benzylidene-thiazolidine-2,4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells.
Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver.
The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
Crosstalk pathway for inhibition of glucocorticoid-induced apoptosis by T cell receptor signaling.
The protooncogene TCL1 is an Akt kinase coactivator.
p90(RSK) blocks bad-mediated cell death via a protein kinase C-dependent pathway.
Quast SA, Berger A, Eberle J
Cell death & disease 2013 Oct 10;4:e839
Cell death & disease 2013 Oct 10;4:e839
PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma.
Gómez-Abad C, Pisonero H, Blanco-Aparicio C, Roncador G, González-Menchén A, Martinez-Climent JA, Mata E, Rodríguez ME, Muñoz-González G, Sánchez-Beato M, Leal JF, Bischoff JR, Piris MA
Blood 2011 Nov 17;118(20):5517-27
Blood 2011 Nov 17;118(20):5517-27
Novel benzylidene-thiazolidine-2,4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells.
Beharry Z, Zemskova M, Mahajan S, Zhang F, Ma J, Xia Z, Lilly M, Smith CD, Kraft AS
Molecular cancer therapeutics 2009 Jun;8(6):1473-83
Molecular cancer therapeutics 2009 Jun;8(6):1473-83
Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver.
Gray MJ, Van Buren G, Dallas NA, Xia L, Wang X, Yang AD, Somcio RJ, Lin YG, Lim S, Fan F, Mangala LS, Arumugam T, Logsdon CD, Lopez-Berestein G, Sood AK, Ellis LM
Journal of the National Cancer Institute 2008 Jan 16;100(2):109-20
Journal of the National Cancer Institute 2008 Jan 16;100(2):109-20
The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
Yu C, Rahmani M, Dai Y, Conrad D, Krystal G, Dent P, Grant S
Cancer research 2003 Apr 15;63(8):1822-33
Cancer research 2003 Apr 15;63(8):1822-33
Crosstalk pathway for inhibition of glucocorticoid-induced apoptosis by T cell receptor signaling.
Jamieson CA, Yamamoto KR
Proceedings of the National Academy of Sciences of the United States of America 2000 Jun 20;97(13):7319-24
Proceedings of the National Academy of Sciences of the United States of America 2000 Jun 20;97(13):7319-24
The protooncogene TCL1 is an Akt kinase coactivator.
Laine J, Künstle G, Obata T, Sha M, Noguchi M
Molecular cell 2000 Aug;6(2):395-407
Molecular cell 2000 Aug;6(2):395-407
p90(RSK) blocks bad-mediated cell death via a protein kinase C-dependent pathway.
Tan Y, Ruan H, Demeter MR, Comb MJ
The Journal of biological chemistry 1999 Dec 3;274(49):34859-67
The Journal of biological chemistry 1999 Dec 3;274(49):34859-67
No comments: Submit comment
No validations: Submit validation data